The Evidence Pack: How Three FDA-Approved Drugs Are Being Tested to Slow Human Aging

For the past century, modern medicine has operated on a 'whack-a-mole' model: wait for a disease to emerge, then attempt to cure it. But epidemiological models show a stark reality. If medical science completely cured all forms of cancer tomorrow, average human life expectancy would only increase by about three years, because aging bodies would simply succumb to heart disease, stroke, or Alzheimer's shortly after. The underlying risk factor for all of these conditions is biological aging itself.[6]

This realization has birthed the field of geroscience—the study of how to treat aging as a root cause rather than just managing its symptoms. Now, a landmark multi-arm clinical trial is putting this theory to the test in humans. Rather than developing novel, multi-million-dollar gene therapies, researchers are testing three cheap, FDA-approved, off-patent drugs: metformin, rapamycin, and an SGLT2 inhibitor. The goal is to see if these existing medications can slow the biological clocks of healthy adults.[1][6]

The first drug in the evidence pack is metformin, a first-line medication for type 2 diabetes that has been used safely for decades. Metformin's entry into the longevity conversation stems from a massive epidemiological anomaly: large-scale retrospective studies revealed that diabetics taking metformin were actually outliving matched, healthy non-diabetics who were not taking the drug. This sparked intense scientific interest in how a simple glucose-lowering pill might be exerting systemic protective effects.[3]

The mechanism behind metformin involves the activation of AMPK, an enzyme that acts as the body's cellular energy sensor. When AMPK is activated, it signals to the body that nutrients are scarce, triggering a mild cellular stress response. This mimics the biological effects of fasting or calorie restriction, prompting cells to repair themselves, clear out misfolded proteins, and reduce systemic inflammation without the patient actually having to starve.[3][6]

The second, and arguably most potent, drug in the trial is rapamycin. Originally discovered in the soil of Easter Island and used primarily as an immunosuppressant for organ transplant patients, rapamycin is considered the gold standard of longevity pharmacology in animal models. In the National Institute on Aging's rigorous Interventions Testing Program (ITP), rapamycin has consistently extended the lifespan of mice by 10% to 25%, delaying the onset of age-related decline across multiple organ systems.[2][5]

Rapamycin works by inhibiting a protein complex called mTOR (mechanistic target of rapamycin). mTOR is essentially the body's growth switch. When nutrients are abundant, mTOR drives cell growth and proliferation. But when mTOR is inhibited, the cell switches from 'growth mode' into 'repair mode'—a process called autophagy, where the cell acts like a biological garbage disposal, breaking down and recycling damaged cellular components that accumulate with age.[2]

However, rapamycin presents a unique clinical challenge. Continuous daily dosing suppresses the immune system, which is why it works for transplant patients but is dangerous for healthy adults. To circumvent this, the new longevity trials are utilizing intermittent dosing—typically once a week. Early human data suggests that pulsed, intermittent doses of rapamycin actually rejuvenate immune function rather than suppress it, improving responses to vaccines in older adults.[2][6]

The third pillar of the trial involves SGLT2 inhibitors, specifically drugs like canagliflozin or empagliflozin. Originally designed to treat diabetes by forcing the kidneys to excrete excess glucose through urine, these drugs have recently stunned cardiologists by demonstrating massive, unexpected protections against heart failure and kidney disease, even in patients who do not have diabetes.[4]

In the context of longevity, SGLT2 inhibitors are showing profound geroprotective effects. In the NIA's testing program, canagliflozin extended the median lifespan of male mice by 14%. Researchers believe the mechanism goes beyond simple glucose control; the drugs appear to blunt systemic inflammation, reduce the burden of senescent 'zombie' cells, and shift the body's metabolism toward burning fat and ketones, which produces less oxidative stress than burning glucose.[4][5]

Designing a clinical trial for longevity presents a massive logistical hurdle: humans live too long to wait for a mortality endpoint. You cannot run a 40-year placebo-controlled trial to see who dies last. Instead, this landmark trial is utilizing advanced 'epigenetic clocks'—blood tests that measure DNA methylation patterns to determine a patient's biological age, which can differ significantly from their chronological age. The trial will track whether these three drugs can slow or reverse the ticking of these epigenetic clocks over a three-to-four-year period.[1][6]

Despite the optimism, the evidence pack carries significant transparent uncertainty. The history of medicine is littered with compounds that cured mice but failed in humans. Mice have vastly different metabolic rates, telomere dynamics, and causes of death compared to humans. What extends a mouse's life by 20% might only offer a marginal benefit to a human, or it might carry unforeseen long-term side effects that animal models cannot predict.[6]

Furthermore, these drugs are not without trade-offs. Metformin, for instance, has been shown in recent clinical studies to blunt the hypertrophic benefits of resistance training. Older adults taking metformin while lifting weights gained less muscle mass than those on a placebo. Because muscle mass and strength are critical predictors of human longevity and fall prevention, prescribing metformin to healthy, active adults remains a highly debated topic among geroscience researchers.[3][6]

If the trial succeeds in proving that these off-patent drugs can safely delay biological aging, it would democratize longevity. Unlike experimental gene therapies or specialized stem cell treatments that could cost hundreds of thousands of dollars, metformin and rapamycin are generic medications that cost pennies to a few dollars a dose. The validation of these compounds would ensure that the first generation of healthspan-extending medicine is accessible to the global public, not just the ultra-wealthy.[6]